Cubi-Molla, P., Shah, K.K., Garside, J., Herdman, M. and Devlin, N.
Several studies have found differences in health state values by age. We investigate whether and how age affects respondents’ Time Trade-Off (TTO) and Visual Analogue Scale (VAS) valuations of hypothetical EQ-5D health states using data from the 1993 MVH UK valuation study.
OHE’s Yan Feng, Mike Herdman, David Parkin and Nancy Devlin have a new paper in Quality of Life Research to exploring whether patients’ self-reported pain can be compared and aggregated in multi-country studies
Zamora, B., Maignen, F., O’Neill, P., Mestre-Ferrandiz, J. and Garau, M.
The European Commission’s (EC) Orphan Medicinal Products Regulation intended to incentivise the research, development and marketing of new treatments for rare and chronically disabling or life-threatening diseases. Marketing authorisation granted to orphan medicinal products (OMPs) is however only the first step; patients have access to medicines once reimbursement or health technology assessment (HTA) decisions are implemented by national health systems.
The aim of this paper is to consider what normative arguments might exist for advocating the use of any given measure of the average in the context of health state values. We begin by providing examples of the importance and implications of the choice of the measure of central tendency in stated preference studies (including both EQ-5D values and corresponding issues in the willingness to pay literature).
OHE is pleased to be working with four MSc students this year. The students, from City University and the London School of Economics, will spend three months at OHE being supervised and trained by various members of the OHE team whilst completing their MSc theses.
A new publication, based on research conducted by OHE, suggests that by 2025 the disability adjusted life year (DALY) burden of dementia will have increased by 42% from the Global Disease Burden (GDB) 2010 estimate.
The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report was initiated and funded by Pfizer Ltd. It specifically considers whether there were changes in the trends due to the adoption of new policies by the SMC, namely the increased use of modifiers when assessing cost-effectiveness (e.g.
An analysis in the trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015 has just been published in an OHE Consulting Report. This report was initiated and funded by Pfizer Ltd.